A5040300802- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Medical Imaging and Pathology Studies
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Tissue Engineering and Regenerative Medicine
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Health Systems, Economic Evaluations, Quality of Life
- Glutathione Transferases and Polymorphisms
- Pain Mechanisms and Treatments
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Multiple and Secondary Primary Cancers
- Pain Management and Opioid Use
- Anesthesia and Pain Management
- Web Data Mining and Analysis
- Occupational exposure and asthma
- Cancer Cells and Metastasis
- Pain Management and Placebo Effect
The University of Sydney
2015-2025
Asbestos Diseases Research Institute
2014-2025
Concord Repatriation General Hospital
2015-2024
Hudson Institute
2022
// Marissa Williams 1, * , Michaela B. Kirschner 2, 13, Yuen Yee Cheng 1 Jacky Hanh 3 Jocelyn Weiss 4 Nancy Mugridge Casey M. Wright Anthony Linton 5 Steven C. Kao 6 J. James Edelman 7 Michael P. Vallely 7, 8 Brian McCaughan 9 Wendy Cooper 10 Sonja Klebe 11 Ruby C.Y. Lin 12 Himanshu Brahmbhatt Jennifer MacDiarmid Nico van Zandwijk 2 Glen Reid Asbestos Diseases Research Institute (ADRI), Sydney, Australia Sydney Medical School, The University of Faculty Pharmacy, EnGeneIC Ltd., Lane Cove,...
Although the prognosis of most patients presenting with malignant pleural mesothelioma (MPM) is poor, a small proportion survives long term. We investigated factors associated survival in large patient series. All registered NSW Dust Diseases Board (2002–2009) were included an analysis prognostic using Kaplan–Meier and Cox regression analysis. On basis these analyses, we developed risk score (Prognostic Index (PI)). identified 910 patients: 90% male; histology (epithelioid 60%; biphasic 13%;...
IntroductionConsolidation durvalumab following platinum-based chemoradiotherapy (CRT) significantly improved overall survival for patients with unresectable stage III non-small cell lung cancer (NSCLC) in the PACIFIC trial. However, older were underrepresented PACIFIC, and subsequent analyses suggested trends toward poorer increased toxicity aged ≥70 years old. We assessed effectiveness safety of consolidation CRT Australian NSCLC.Materials MethodsThis retrospective observational study was...
To identify the approximately 12% with inherited cancer predisposition, all men metastatic prostate (mPC) should be offered germline genetic testing. This guides treatment choices and impacts prevention in family. Limited services globally present a barrier to study tested potential solution, "mainstreaming," where counseling testing are performed by patient's oncologist.Men mPC at three Australian sites were their medical oncology appointment. Panel (ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM,...
Malignant pleural mesothelioma (MPM) is an aggressive malignancy linked to asbestos exposure. On a genomic level, MPM characterized by frequent chromosomal deletions of tumor suppressors, including microRNAs. MiR-137 plays suppressor role in other cancers, so the aim this study was characterize it and its target Y-box binding protein 1 (YBX1) MPM.Expression, methylation, copy number status miR-137 host gene MIR137HG were assessed polymerase chain reaction. Luciferase reporter assays...
Malignant pleural mesothelioma (MPM) is an aggressive tumour originating in the thoracic mesothelium. Prognosis remains poor with 9- to 12-month median survival, and new targets for treatments are desperately needed. Utilising RNA interference (RNAi)-based screen of 40 genes overexpressed tumours, including involved control cell cycle, DNA replication repair, we investigated potential therapeutic MPM. Following vitro characterisation effects target silencing on MPM cells, candidates were...
Abstract Background Finding effective and curative treatment for mesothelioma remains challenging. While the introduction of immunotherapy combinations using ipilimumab (anti-CTLA-4) nivolumab (anti-PD-1) have offered hope some patients, a large proportion cases, particularly epithelial subtype, minimal benefit from this. Methods Our study was inspired by results AdvanTG-105 phase I clinical trial, which showed partial response with anti-TIGIT/PD-1 in two epithelioid patients. Here, we...
Traditional studies using cancer cell lines are often performed on a two-dimensional (2D) culture model with low success rate of translating to Phase I or II clinical studies. In comparison, the advent developments three-dimensional (3D) has been championed as latest cellular system that better mimics in vivo conditions and pathological such cancer. comparison biospecimens taken from tissue, details gene expression 3D models largely undefined, especially mesothelioma - an aggressive very...
Aims Mesothelin (MSLN) is a cancer‐associated antigen that overexpressed in malignancies such as mesothelioma, pancreatic and ovarian cancer. It also target for novel personalised therapies, including antibodies, antibody–drug conjugates chimeric receptor T cells. Immunohistochemistry may predict those who would best respond to anti‐mesothelin therapies guide decisions therapeutic strategy. This study aimed assess the intensity distribution of MSLN immunostaining determine prognostic value...
The relationship between inflammation and cancerous growth has been extensively investigated over the past 150 years. Following Virchow’s identification of leukocytes within neoplastic tissue in 1863 (1), role inflammatory cells pathways pathogenesis a variety tumour groups become well established. In malignancies, environmental infective agents are seen to play critical roles production damage reactions. Furthermore, cytokines, chemokines angiogenic factors produced chronic states provide...
The diagnosis of malignant pleural mesothelioma (MPM) can be difficult, in part due to the difficulty distinguishing between MPM and reactive mesothelial hyperplasia (RMH). tumor suppressor gene, CDKN2A, is frequently silenced by epigenetic mechanisms many cancers; case it mostly via genomic deletion. Co-deletion CDKN2A methylthioadenosine phosphorylase (MTAP) genes has been researched extensively discovered a highly specific characteristic MPM. Most studies have used FISH detect deletion...
ABSTRACT Background and objective Whilst the impact of clinicopathological factors on prognosis malignant pleural mesothelioma ( MPM ) is well understood, socioeconomic geographic have received less attention. We analysed relationship between upon survival treatment provision in a large series patients with . Methods assessed awarded compensation 2002 2009 additional incidence data from New South Wales NSW Cancer Registry. The remoteness, distance oncological multidisciplinary team MDT Index...
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, utility in the current clinical setting. In this study, we utilised a large collection of lines and tissue samples study role E-cadherin (CDH1) microRNA on efficacy FAK MPM. The immunohistochemistry (IHC) results showed that majority FFPE exhibited either absence of, or very low,...